Literature DB >> 23116467

Drug repurposing in chemical genomics: can we learn from the past to improve the future?

William H Bisson1.   

Abstract

More needs to be done by the private sector to optimize the drug discovery and development pipeline. In addition, significant efforts should also be focused on the understanding of mechanism of diseases, on the characterization of unexplored biochemical pathways and on the validation of new protein targets. Chemical genomics, which uses chemical probes to help understand the complexity of biological systems at the gene and protein levels, has proven in recent years to be an important tool. Experimental and computational chemical genomic screenings have been used by the private sector and recently also by academia and non-profit institutions for drug repurposing or repositioning to find new indications for known drugs. A detailed overview of the current initiatives in drug repurposing, initiated by the major governmental funding agencies around the world is reported. The push towards greater efficiency is encouraging drug repurposing and other techniques in chemical genomics. Finding the best ways to improve translational research and accelerate the regulation of clinical phases means being able to launch safer drugs into the market faster.

Mesh:

Substances:

Year:  2012        PMID: 23116467     DOI: 10.2174/156802612804547344

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  11 in total

1.  Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.

Authors:  Lei Chen; Yu-Hang Zhang; Mingyue Zheng; Tao Huang; Yu-Dong Cai
Journal:  Mol Genet Genomics       Date:  2016-08-16       Impact factor: 3.291

2.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

3.  Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans.

Authors:  Elizabeth W Hunsaker; Katherine J McAuliffe; Katherine J Franz
Journal:  J Biol Inorg Chem       Date:  2020-06-15       Impact factor: 3.358

4.  Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen.

Authors:  Arielle Butts; Jennifer A Martin; Louis DiDone; Erin K Bradley; Mitchell Mutz; Damian J Krysan
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

5.  Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory.

Authors:  Hermann A M Mucke
Journal:  Front Pharmacol       Date:  2017-12-15       Impact factor: 5.810

6.  DeCoST: A New Approach in Drug Repurposing From Control System Theory.

Authors:  Thanh M Nguyen; Syed A Muhammad; Sara Ibrahim; Lin Ma; Jinlei Guo; Baogang Bai; Bixin Zeng
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

7.  The proton pump inhibitor, lansoprazole, prevents the development of non-traumatic osteonecrosis of the femoral head: an experimental and prospective clinical trial.

Authors:  Ima Kosukegawa; Shunichiro Okazaki; Motohisa Yamamoto; Satoshi Nagoya; Chisako Suzuki; Junya Shimizu; Hiroki Takahashi; Toshihiko Yamashita
Journal:  Eur J Orthop Surg Traumatol       Date:  2020-01-14

8.  Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.

Authors:  Arielle Butts; Kristy Koselny; Yeissa Chabrier-Roselló; Camile P Semighini; Jessica C S Brown; Xuying Wang; Sivakumar Annadurai; Louis DiDone; Julie Tabroff; Wayne E Childers; Magid Abou-Gharbia; Melanie Wellington; Maria E Cardenas; Hiten D Madhani; Joseph Heitman; Damian J Krysan
Journal:  MBio       Date:  2014-02-11       Impact factor: 7.867

9.  Fighting viruses with antibiotics: an overlooked path.

Authors:  Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2016-08-05       Impact factor: 5.283

10.  Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.

Authors:  Gizem Tatar; Ezgi Ozyurt; Kemal Turhan
Journal:  Biotechnol Prog       Date:  2020-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.